The National Biosafety Authority (NBA) has approved two applications on HIV vaccine trials and Malaria control for the Centre for Infectious Disease Research in Zambia (CIDRZ) and Macha Research Trust respectively.
The CIDRZ permit is for conducting research trials on the safety and immunogenicity of HVTN 120/ALVAC and will be conducted in Lusaka while the malaria control will be done at Macha Research Trust, Choma in Southern Province.
NBA Chief Executive Officer (CEO) Mr Lackson Tonga said the approval of the Permits follows the two applicants meeting the required set standards.
“CIDRZ’s Phase 1/2a clinical trial will evaluate the safety and immunogenicity of ALVAC-HIV (vCP2438) genetically modified vaccine in healthy HIV-uninfected adult participants. The permit has been awarded after the organization met the requirements in accordance with Section 18 of the Biosafety Act No. 7 of 2007,” he said.
“The NBA Board, during the 4th quarter meeting for the year 2017, approved the permit application for CIDRZ. The vaccine trials will be conducted in Matero, Lusaka and the permit is valid for three years.”